Format

Send to

Choose Destination
See comment in PubMed Commons below

[Comparison of the efficacy of gadobutrol and multihance in contrast-enhanced MRI for diagnosis of brain metastasis in lung cancer].

[Article in Chinese]

Author information

1
Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China.

Abstract

OBJECTIVE:

To investigate the diagnostic efficacy of gadobutrol for assessing brain metastases in lung cancer patients in comparison with multihance.

METHODS:

21 patients with lung cancer suspected of brain metastasis were enrolled in this study. All patients underwent twice MRI scans on a 3.0T MRI scanner (Siemens MAGENETOM Trio) with 8-channel head coil, first with 0.5 mol/L multihance and then with 1.0 mol/L gadobutrol as contrast agent. The dosage of contrast agent was set at 0.1 mmol/kg body mass. The interval between the two scans was 24-72 hours. The detection and delineation of lesions were evaluated visually. The signal-to-noise ratios (SNR), contrast-to-noise ratios (CNR) of lesion to normal brain white matter and the percentage of lesion enhancement were calculated and compared between the two scans by 2 experienced neuroradiologists.

RESULTS:

One patient was excluded because he received radiation therapy between the two scans. 15 patients were found to have brain metastases with a total of 35 lesions. There were no statistical differences between the two scans in SNR, CNR and percentage enhancement for both normal brain and lesions (t = 0.545, P = 0.592; t = 1.143, P = 2.267; t = 0.592, P = 0.557; t = 0.473, P = 0.639).

CONCLUSION:

Half-dose gadobutrol (1.0 mol/L) can achieve the same enhancement effects compared with full-dose multihance (0.5 mol/L).

PMID:
22997905
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center